Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lopinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lopinavir SCHEMBL825826 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL28365789 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL13065521 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL21775 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL18898529 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL3042268 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL13370718 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL22241592 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL22382744 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL12270816 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864369-B2 | New crystal structure of lopinavir; enzyme inhibitors of human immunodeficiency virus (HIV) protease for treating HIV infections | ABBOTT LABORATORIES (US) | 2005-03-08 | — | — | US | claimed |
| US-6608198-B2 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBOTT LABORATORIES | 2003-08-19 | — | — | US | claimed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | claimed |
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | THE J. DAVID GLADSTONE INSTITUTES (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023088358-A1 | TREATMENT OF CANCER WITH A GLUCOCORTICOID RECEPTOR AGONIST AND AN HIV PROTEASE INHIBITOR | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-05-25 | — | — | WO | disclosed |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220364119-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
| US-8058433-B2 | Crystalline pharmaceutical | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070027172-A1 | Crystalline pharmaceutical | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | disclosed |
| US-20050124810-A1 | Purity; hydrate forms | DICKMAN DANIEL A (US) | 2005-06-09 | — | — | US | disclosed |
| US-6864369-B2 | New crystal structure of lopinavir; enzyme inhibitors of human immunodeficiency virus (HIV) protease for treating HIV infections | ABBOTT LABORATORIES (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030191313-A1 | New crystal structure of lopinavir; enzyme inhibitors of human immunodeficiency virus (HIV) protease for treating HIV infections | ABBVIE INC. | 2003-10-09 | — | — | US | disclosed |
| US-6608198-B2 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBOTT LABORATORIES | 2003-08-19 | — | — | US | disclosed |
| EP-1268442-A2 | CRYSTALLINE PHARMACEUTICAL | Abbott Laboratories (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20010051721-A1 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBVIE INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001074787-A2 | CRYSTALLINE PHARMACEUTICAL | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124810-A1 | Purity; hydrate forms | SAMHD1, ACE, CYP3A4 | CYP3A4 3/4885ABCC3 173/4885ABCC4 127/4885 |
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | NSUN2, IRF3, DNMT3B | CYP3A4 4068/4885ABCC3 3910/4885ABCC4 4161/4885 |
| US-20010051721-A1 | Hydrated forms of lopinavir; HIV protease inhibitor | SERPINB1, HPN, ACE | CYP3A4 59/4885ABCC3 260/4885ABCC4 331/4885 |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | HAVCR2, CD4, MAVS | CYP3A4 3109/4885ABCC3 3470/4885ABCC4 3842/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | CYP3A4 4113/4885ABCC3 3183/4885ABCC4 3709/4885 |
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | CHD1L, SMARCC1, CHD1 | CYP3A4 4332/4885ABCC3 2158/4885ABCC4 1913/4885 |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | GSK3B, GSK3A, GSKIP | CYP3A4 2605/4885ABCC3 4418/4885ABCC4 4871/4885 |
| US-20070027172-A1 | Crystalline pharmaceutical | PYGL, ACE, HDLBP | CYP3A4 21/4885ABCC3 112/4885ABCC4 133/4885 |
| US-20030191313-A1 | New crystal structure of lopinavir; enzyme inhibitors of human immunodeficiency virus (HIV) protease for treating HIV infections | SERPINB1, ACE, PEPD | CYP3A4 118/4885ABCC3 1192/4885ABCC4 1228/4885 |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | VEGFA, ADAR, EIF2AK2 | CYP3A4 2418/4885ABCC3 2512/4885ABCC4 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.